Meyenburg Cancer Research Award: "Revolutionary Science Meets Clinical Impact – Celebrating a Pioneer in Cancer Immunotherapy"

This year’s Meyenburg Cancer Research Award ceremony, honors Dr. Michel Sadelain, a visionary who transformed patients’ cells into “living drugs” that fight cancer.

Dr. Sadelain’s groundbreaking work on chimeric antigen receptor (CAR) T-cell therapy has fundamentally changed how we treat certain cancers. From the initial concept to FDA approval in 2017, his journey represents one of the most significant breakthroughs in modern oncology – giving hope to patients who previously had none.

Dr. Sadelain’s remarkable contributions have been recognized with prestigious accolades, including the Breakthrough Prize for Life Sciences and the Canada Gairdner International Award. He is a member of the American Academy of Arts and Sciences and the National Academy of Medicine of France. The Meyenburg Cancer Research Award honors Dr. Sadelain’s outstanding efforts to improve the clinical care of cancer patients through scientific inquiry, as well as his engaging and collaborative personality.

Confirmed Speakers:

• Michel Sadelain
• Andreas Mackensen (Erlangen University Hospital)
• Fabrice André (Institut Gustave Roussy)
• Hafsa Munir (DKFZ & Helmholtz Institute for Translational Oncology Mainz)
• Franziska Blaeschke (DKFZ & Hopp Children's Cancer Center Heidelberg)

Register